Patent number: 10654848
Abstract: Disclosed herein are compounds of formula (I), and pharmaceutical compositions comprising the same. The compounds of formula (I) are neutrophilic inflammation inhibitors, thus, they are useful for treatment and/or prophylaxis of inflammatory diseases and/or disorders associated with abnormal activation of neutrophils, such as ARDS, ALI, COPD, lung fibrosis, chronic bronchitis, pulmonary emphysema, ?-1 anti-trypsin deficiency, cystic fibrosis, idiopathic pulmonary fibrosis, liver injury, steatohepatitis, liver fibrosis, damages caused by ischemia and reperfusion, myocardial infarction, shock, stroke, and organ transplantation, ulcerative cholitis, vasculitis, SLE, sepsis, SIRS, arthritis, psoriasis, atopic dermatitis, and inflammatory skin diseases.
Type:
Grant
Filed:
November 9, 2018
Date of Patent:
May 19, 2020
Assignees:
Chang Gung University of Science and Technology, Chang Gung University, Kaohsiung Medical University
Inventors:
Tsong-Long Hwang, Yeh-Long Chen, Cherng-Chyi Tzeng, Chih-Hua Tseng